Clinical Trials Directory

Trials / Completed

CompletedNCT02943291

Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Norwegian University of Science and Technology · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The primary aim of this trial is to investigate adipose tissue function in women with and without polycystic ovary syndrome (PCOS). PCOS is a common endocrine disorder in young women. The pathogenesis behind PCOS is complex and only partly understood, and deeper mechanistic insight is needed. Insulin resistance is a central feature of PCOS, and recent studies have suggested that this is linked to aberrant adipose tissue function. Exercise training has been found to improve the symptoms in PCOS, but we need more knowledge about why. While processes involved in skeletal muscle oxidative remodeling are well described, it is to a large extent unknown whether the oxidative capacity of human adipose tissue is modified by endurance training. The women included in this study will be matched (for body mass index, body weight, and age) to participants in another study. This will enable the investigators to do a comparison between cases (women with PCOS) and controls (women without PCOS) at baseline, and to assess the responses to exercise training in adipose tissue.

Conditions

Interventions

TypeNameDescription
BEHAVIORAL4x4 minutes high intensity interval trainingTreadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
BEHAVIORAL10x1 minute high intensity interval trainingTreadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.

Timeline

Start date
2016-10-24
Primary completion
2022-01-31
Completion
2022-01-31
First posted
2016-10-24
Last updated
2023-03-17

Locations

2 sites across 2 countries: Australia, Norway

Source: ClinicalTrials.gov record NCT02943291. Inclusion in this directory is not an endorsement.